|
EP0656887B1
(en)
|
1992-08-25 |
1998-10-28 |
G.D. Searle & Co. |
Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
|
|
KR100495690B1
(ko)
|
1996-01-26 |
2005-11-08 |
비르코 비브이비에이 |
인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법
|
|
US6242187B1
(en)
|
1996-01-29 |
2001-06-05 |
Virologic, Inc. |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
|
JP2001512036A
(ja)
*
|
1997-07-30 |
2001-08-21 |
バイアラジック・インコーポレーテッド |
抗ウイルス薬剤感受性および耐性を測定するための組成物および方法、並びに抗ウイルス薬剤をスクリーニングするための組成物および方法
|
|
WO1999051776A1
(en)
*
|
1998-04-07 |
1999-10-14 |
Southern Research Institute |
High-throughput method for screening for antiviral activity
|
|
AU772511B2
(en)
*
|
1998-05-26 |
2004-04-29 |
Virologic, Inc. |
Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
|
|
US7037644B1
(en)
|
1998-05-26 |
2006-05-02 |
Virologic, Inc. |
Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
|
|
DE69924118T2
(de)
*
|
1998-06-19 |
2005-12-22 |
The Government of the United States of America, as represented by the Secretary Centers for Disease and Prevention, Office of Technology |
Verfahren und reagentiensatz zur erkennung von antiviralen wirkstoff resistenzen
|
|
US6787126B1
(en)
|
1998-06-19 |
2004-09-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method and kit for detecting resistance to antiviral drugs
|
|
US20030148307A1
(en)
|
1998-06-19 |
2003-08-07 |
Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention |
Method and kit for detecting resistance to antiviral drugs
|
|
EP1015642A4
(en)
*
|
1998-06-24 |
2005-03-23 |
Virologic Inc |
Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
|
|
DE60022036T2
(de)
|
1999-05-28 |
2006-06-08 |
Virco N.V. |
Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
|
|
CA2422489A1
(en)
*
|
2000-09-15 |
2002-03-21 |
Virologic, Inc. |
Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
|
|
DE60137580D1
(de)
|
2000-10-20 |
2009-03-19 |
Virco Bvba |
Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz
|
|
AU2002226316B2
(en)
|
2000-10-20 |
2008-06-26 |
Virco Bvba |
Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
|
|
US7247439B1
(en)
|
2001-06-04 |
2007-07-24 |
Monogram Biosciences, Inc. |
Method of evaluating a patient antibody response to envelope proteins of a virus
|
|
US7097970B2
(en)
|
2001-06-04 |
2006-08-29 |
Monogram Biosciences, Inc. |
Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
|
|
CA2466497A1
(en)
|
2001-11-08 |
2003-05-15 |
Tibotec Pharmaceuticals Ltd. |
Protease assay for therapeutic drug monitoring
|
|
WO2004003223A2
(en)
|
2002-07-01 |
2004-01-08 |
Tibotec Pharmaceuticals Ltd. |
New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
|
|
EP1520247B1
(en)
|
2002-07-01 |
2009-05-27 |
Tibotec Pharmaceuticals Ltd. |
Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
|
|
DE20218008U1
(de)
|
2002-11-21 |
2003-03-06 |
FESTO AG & Co., 73734 Esslingen |
Anordnung von mehreren Handhabungsvorrichtungen
|
|
US8603736B2
(en)
|
2004-06-07 |
2013-12-10 |
Monogram Biosciences, Inc. |
Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
|
|
WO2006089046A2
(en)
|
2005-02-18 |
2006-08-24 |
Monogram Biosciences, Inc. |
Methods and compositions for determining anti-hiv drug susceptibility and replication capacity of hiv
|
|
US8178291B2
(en)
|
2005-02-18 |
2012-05-15 |
Monogram Biosciences, Inc. |
Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
|
|
EP2458019A3
(en)
|
2005-05-27 |
2012-07-25 |
Monogram BioSciences, Inc. |
Methods and compositions for determining resistance of HIV-1 to protease inhibitors
|
|
WO2006133266A2
(en)
|
2005-06-06 |
2006-12-14 |
Monogram Biosciences, Inc. |
Methods for determining resistance or susceptibility to hiv entry inhibitors
|
|
US8071284B2
(en)
|
2005-06-06 |
2011-12-06 |
Monogram Biosciences, Inc. |
Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs
|
|
WO2007146336A2
(en)
|
2006-06-13 |
2007-12-21 |
Monogram Biosciences, Inc. |
Molecular determinants associated with enhanced ability to enter cells expressing cxcr4
|
|
US8338101B2
(en)
*
|
2007-01-23 |
2012-12-25 |
Virco Bvba |
Method for designing a drug regime for HIV-infected patients
|
|
US9581595B2
(en)
|
2007-02-26 |
2017-02-28 |
Laboratory Corporation Of America Holdings |
Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
|
|
JPWO2018030534A1
(ja)
*
|
2016-08-10 |
2019-06-13 |
国立研究開発法人理化学研究所 |
Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法
|
|
RU2646472C1
(ru)
*
|
2016-10-07 |
2018-03-05 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации |
Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей
|
|
CN110382009A
(zh)
*
|
2016-12-29 |
2019-10-25 |
富荣吉有限责任公司 |
Retro-HBV和Lenti-HBV的混合载体及构建体
|
|
CN109722465B
(zh)
*
|
2019-01-07 |
2022-02-01 |
福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) |
一种hiv耐药检测载体和构建方法
|
|
WO2021259345A1
(zh)
*
|
2020-06-24 |
2021-12-30 |
厦门大学 |
靶向HBV cccDNA的药物筛选模型及方法
|